Sorafenib is the standard treatment for patients with advanced
hepatocellular carcinoma (HCC). However, the median overall survival (OS) benefit is only ~3 months, and sufficient
biomarkers predicting treatment response are not available. The aim of the present study was to evaluate
miRNA expression patterns from HCC tissue biopsies as potential
biomarkers in patients under
sorafenib treatment. Nineteen patients with advanced HCC treated with
sorafenib were included.
RNA was extracted from
formalin-fixed
paraffin-embedded (FFPE) liver biopsies.
miRNA expression profiling of 818 mature
miRNAs was performed using GeneChip®
miRNA Array 2.0 (Affymetrix). Global
miRNA patterns were assessed using unsupervised hierarchical clustering analysis (UCA), and specific
miRNAs with correlation with disease control rate (DCR) or good OS were evaluated by pairwise supervised analyses. UCA divided the patients into three distinct groups by their
miRNA expression patterns. However, DCR or OS did not correlate with these sub-groups. We have identified several
miRNAs that correlated with either DCR or OS (P<0.05). However, with correction for multiple testing, these results did not reach statistical significance in this small cohort. Global
miRNA analysis from very low input
RNA deriving from liver biopsies showed distinctive clustering of molecular sub-groups in patients with intermediate and advanced HCC. Clinical response including OS under
sorafenib did not correlate with global
miRNA expression patterns, but we have identified candidate
miRNAs for the prediction of DCR and OS to be evaluated in prospective studies and larger patient cohorts.